Online Inquiry

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.


Digestive Cancer

Digestive cancers, such as esophageal, gastric, pancreatic, hepatic, and colorectal cancers, are a significant global health concern due to their high mortality rates. At our company, a leader in the pharmaceutical industry, we are committed to providing specialized digestive system cancer research and development services.

Introduction to Digestive Cancer

Digestive cancer encompasses a group of malignancies that affect the organs involved in the digestive system, including the esophagus, stomach, pancreas, liver, and colon. These cancers arise from the uncontrolled growth and proliferation of cells in these organs, leading to the formation of tumors.

Chronic inflammation has been linked to the development of digestive cancers, such as chronic gastritis predisposing individuals to gastric cancer, chronic hepatitis leading to hepatocellular carcinoma, and chronic inflammatory bowel disease increasing the risk of colorectal cancer. Inflammatory processes can initiate and promote carcinogenesis through various mechanisms, including genotoxicity, release of genotoxic substances, increased cell proliferation, and cellular functional changes.

Fig.1 Activators or inhibitors of histone methylation modifiers in digestive cancers.Fig.1 Activators or inhibitors of histone methylation modifiers in digestive cancers. (Chen, Yuan, et al., 2020)

Targets of Digestive Cancer Therapy Development

  • Various genetic alterations are associated with digestive cancers, providing insights into potential therapeutic targets. For example, mutations in the TP53 gene are commonly found in esophageal and gastric cancers, while KRAS mutations are prevalent in pancreatic and colorectal cancers.
  • Targeting specific molecules and pathways involved in digestive cancer progression is a promising approach for therapy development. In digestive cancers, neurotrophins, such as NGF, BDNF, and NT3, and their receptors, including Trk receptors and p75NTR, have been implicated in tumor development and progression.

Therapy Development of Digestive Cancer


Chemotherapy utilizes drugs to kill cancer cells or inhibit their growth. It is often used as an adjuvant therapy after surgery to eliminate any remaining cancer cells or as a primary therapeutics for advanced or metastatic digestive cancer.

Gene Therapy

Tumor suppressor genes, such as TP53, play a crucial role in preventing the uncontrolled growth of cancer cells. In gene therapy, the delivery of functional tumor suppressor genes can restore their activity and inhibit tumor progression.


Immunotherapy utilizes the inherent power of the body's immune system to identify and eliminate cancer cells. This approach involves enhancing the immune response or employing immune checkpoint inhibitors to hinder cancer cells from evading immune surveillance.

Our Services

Our team of expert researchers and scientists at Our Company is focused on identifying and targeting specific molecules and pathways involved in digestive cancer. By leveraging cutting-edge technologies and a deep understanding of the underlying biology, we strive to develop diagnostics and novel therapies that can effectively combat digestive cancer.

Types of Digestive Cancers

Therapy Development Platforms

Animal models provide valuable insights into the effectiveness and safety of potential therapies before moving to human trials. Our company is focused on developing robust animal models that accurately mimic the characteristics of digestive system cancers. These models allow us to evaluate the effectiveness of our therapies and optimize therapy development strategies.

If you are interested in our services, please feel free to contact us for more details and quotation information of related services.


  • Chen, Yuan, et al. "The role of histone methylation in the development of digestive cancers: a potential direction for cancer management." Signal transduction and targeted therapy 5.1 (2020): 143.
  • Stenzinger, Albrecht, and Wilko Weichert. "Genetic profiling of cancers of the digestive system: biological insights and clinical implications." Pathobiology 84.6 (2018): 306-322.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Related Services

Copyright © Protheragen. All rights reserves.